Address: 301 A-Leela Business Park,M.V. Road, Andheri
Tel: +91 22 5677 4242
Quintiles Transnational is a pharmaceutical services company offering clinical, commercial, consulting and capital services. The Quintiles network consists of more than 20,000 employees in 60 countries.
Quintiles manages clinical trials on behalf of pharmaceutical customers, and provides the following services:
Management of clinical trials, data, projects and providing laboratory services
Providing customers with sales force, product and brand solutions.
Providing data-driven recommendations to help customers achieve success.
Creating strategic partnerships through financing and operational solutions.
Quintiles India is located amidst a rapidly growing local pharmaceutical market. With five offices spread across the country, we help clients take advantage of a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and tertiary care and teaching hospitals available for trials.
Other advantages: Quintiles India has solid relationships with leading medical centers and experienced English-speaking investigators. All studies are conducted to FDA and ICH GCP standards. Urban India’s literate population provides fast, efficient access to broad population groups with common and special disease profiles, allowing for rapid patient recruitment and faster study start-ups.
Quintiles helped develop or commercialize all of 2009’s top 50 best selling drugs or compounds and nearly 90% of all breakthrough products released on the market between 1996 and 2008.
Key Services in India:
Access to patients
Central laboratory services
Clinical monitoring and site management
Data management offering a functional service provider (FSP) business model
ECG monitoring services
Access through Our India Team to Quintiles Worldwide:
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April,…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the…